Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development
Yinliang Bai, Yujun Qiao, Mingming Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116123-116123
Closed Access | Times Cited: 9

Showing 9 citing articles:

Protein phosphorylation and kinases: Potential therapeutic targets in necroptosis
Yihui Shi, Chengkun Wu, Jiayi Shi, et al.
European Journal of Pharmacology (2024) Vol. 970, pp. 176508-176508
Closed Access | Times Cited: 6
Targeting necroptosis in MCF-7 breast cancer cells: In Silico insights into 8,12-dimethoxysanguinarine from Eomecon Chionantha through molecular docking, dynamics, DFT, and MEP studies
Maram B. Alhawarri, Mohammad G. Al‐Thiabat, Amit Dubey, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0313094-e0313094
Open Access
Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors as Potential Treatment for Several Inflammatory and Neurodegenerative Diseases
Ahmed F. Abdel‐Magid
ACS Medicinal Chemistry Letters (2025)
Open Access
Advances in the Study of Necroptosis in Vascular Dementia: Focus on Blood–Brain Barrier and Neuroinflammation
Yuemin Qiu, Lin Cheng, Yinyi Xiong, et al.
CNS Neuroscience & Therapeutics (2025) Vol. 31, Iss. 2
Open Access
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 2, pp. 177-178
Open Access | Times Cited: 1
Novel Isoxazolidines as RIPK1 Inhibitors for Treating Alzheimer’s Disease, Multiple Sclerosis, and Amyotrophic Lateral Sclerosis
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 4, pp. 447-448
Open Access
Non-apoptotic cell death in osteoarthritis: Recent advances and future
Pengfei Ji, Ziyu Zhou, Jinyuan Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 179, pp. 117344-117344
Open Access
PANoptosis: a new insight for oral diseases
Xinyi Jiang, Tingting Fu, Lan Huang
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access
Unraveling the role of RIPKs in diabetic kidney diseases and its therapeutic perspectives
Anju Ambujakshan, Bidya Dhar Sahu
Biochemical Pharmacology (2024), pp. 116642-116642
Closed Access
Design and synthesis of pyridazin‐4‐one derivatives as necroptosis inhibitors
Yuxiang An, Xia Peng, Tieyu Wang, et al.
Archiv der Pharmazie (2024)
Closed Access
Antiviral-effect of nitrogen-containing compounds isolated from Sarcodon imbricatus on influenza A virus through regulation of ZBP-1 mediated necroptosis
Hye Jin Yang, Eun-Bin Kwon, Young Soo Kim, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117732-117732
Open Access
Page 1

Scroll to top